Details of the Drug

General Information of Drug (ID: DMK1GBJ)

• Drug Name: Trazodone
• Synonyms: Beneficat; Desirel; Sideril; Tradozone; Trazalon; Trazodil; Trazodon; Trazodona; Trazodonum; Trazolan; Trazonil; Trialodine; Trittico; Desyrel Dividose; Trazodona [Spanish]; Trazodone Hcl; Trazodonum [Latin]; Beneficat (TN); Deprax (TN); Desirel (TN); Desyrel (TN); Desyrel(trazodone hcl salt); Molipaxin (TN); Thombran (TN); Trazodona [INN-Spanish]; Trazodone (Desyrel); Trazodone (INN); Trazodone [INN:BAN]; Trazodonum [INN-Latin]; Trazorel (TN); Trialodine (TN); Trittico (TN); 2-(3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; 8-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-1,7,8-triazabicyclo[4.3.0]nona-2,4,6-trien-9-one hydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1]

• Therapeutic Class: Antidepressants
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 371.9
  Logarithm of the Partition Coefficient (xlogp); 2.8
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 20,216 +/- 5021 mcgh/L [2]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3 h [2]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
  Bioavailability: The bioavailability of drug is 44% [2]
  Clearance: The total body clearance of drug is 5.3 +/- 0.9 L/h [4]
  Elimination: Less than 1% of an oral dose is excreted unchanged in the urine [5]
  Half-life: The concentration or amount of drug in body reduced by one-half in 7.3 +/- 0.8 hours [4]
  Metabolism: The drug is metabolized via the liver [5]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 23.0495 micromolar/kg/day [6]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.08% [7]
  Vd: The volume of distribution (Vd) of drug is 0.84 +/- 0.16 L/kg [8]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.2 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Poisoning and toxicity	Not Available	CYP2D6	OTZJC802	[9]

• Chemical Identifiers:
  Formula: C19H22ClN5O
  IUPAC Name: 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one
  Canonical SMILES: C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl
  InChI: InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2
  InChIKey: PHLBKPHSAVXXEF-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 5533
  ChEBI ID: CHEBI:9654
  CAS Number: 19794-93-5
  DrugBank ID: DB00656
  TTD ID: D00USF
  VARIDT ID: DR00490
  INTEDE ID: DR1631
  ACDINA ID: D00698

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Modulator	[10]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Modulator	[10]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[12]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[13]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[13]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5-hydroxytryptamine receptor 1A (HTR1A)	OT38K9MK	5HT1A_HUMAN	Protein Interaction/Cellular Processes	[14]
5-hydroxytryptamine receptor 2C (HTR2C)	OT6H8DE0	5HT2C_HUMAN	Protein Interaction/Cellular Processes	[15]
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Gene/Protein Processing	[16]
Bone morphogenetic protein 6 (BMP6)	OT9WN536	BMP6_HUMAN	Gene/Protein Processing	[16]
Cystine/glutamate transporter (SLC7A11)	OTKJ6PXW	XCT_HUMAN	Gene/Protein Processing	[16]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Gene/Protein Processing	[17]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Drug Response	[9]
Hepatocyte growth factor receptor (MET)	OT7K55MU	MET_HUMAN	Gene/Protein Processing	[16]
Interleukin-1 alpha (IL1A)	OTPSGILV	IL1A_HUMAN	Gene/Protein Processing	[16]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Gene/Protein Processing	[16]

Molecular Expression Atlas of This Drug

• The Studied Disease: Depression
• ICD Disease Classification: 6A70-6A7Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
5-HT 1A receptor (HTR1A)	DTT	HTR1A	2.18E-01	-0.11	-0.51
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	5.16E-01	4.53E-02	3.54E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	2.06E-01	-1.87E-01	-6.20E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	3.40E-01	1.04E-01	7.11E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.43E-01	2.19E-03	1.72E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	3.18E-03	2.30E-01	2.71E+00
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	8.32E-01	4.74E-02	1.73E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Trazodone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Aprepitant	DM053KT	Moderate	Decreased metabolism of Trazodone caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[18]
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Trazodone and Sertraline.	Depression [6A70-6A7Z]	[19]
Trimipramine	DM1SC8M	Major	Additive serotonergic effects by the combination of Trazodone and Trimipramine.	Depression [6A70-6A7Z]	[19]
Cyclobenzaprine	DM1YBRM	Major	Additive serotonergic effects by the combination of Trazodone and Cyclobenzaprine.	Depression [6A70-6A7Z]	[19]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Trazodone and Nefazodone.	Depression [6A70-6A7Z]	[19]
Paroxetine	DM5PVQE	Major	Additive serotonergic effects by the combination of Trazodone and Paroxetine.	Depression [6A70-6A7Z]	[19]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Trazodone and Selegiline.	Depression [6A70-6A7Z]	[20]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Trazodone and Vortioxetine.	Depression [6A70-6A7Z]	[19]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Trazodone and Isocarboxazid.	Depression [6A70-6A7Z]	[20]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Trazodone and Milnacipran.	Depression [6A70-6A7Z]	[19]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of Trazodone and Escitalopram.	Depression [6A70-6A7Z]	[21]
Tranylcypromine	DMGB5RE	Major	Additive serotonergic effects by the combination of Trazodone and Tranylcypromine.	Depression [6A70-6A7Z]	[20]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Trazodone and Desvenlafaxine.	Depression [6A70-6A7Z]	[19]
Clomipramine	DMINRKW	Major	Additive serotonergic effects by the combination of Trazodone and Clomipramine.	Depression [6A70-6A7Z]	[19]
Doxepin	DMPI98T	Major	Additive serotonergic effects by the combination of Trazodone and Doxepin.	Depression [6A70-6A7Z]	[19]
Maprotiline	DMPWB7T	Major	Additive serotonergic effects by the combination of Trazodone and Maprotiline.	Depression [6A70-6A7Z]	[19]

Coadministration of a Drug Treating the Disease Different from Trazodone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Trazodone and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[22]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Trazodone and Ivosidenib.	Acute myeloid leukaemia [2A60]	[23]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Idarubicin.	Acute myeloid leukaemia [2A60]	[24]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Daunorubicin.	Acute myeloid leukaemia [2A60]	[24]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Arn-509.	Acute myeloid leukaemia [2A60]	[25]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Gilteritinib.	Acute myeloid leukaemia [2A60]	[24]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Oliceridine.	Acute pain [MG31]	[24]
Galantamine	DMEO794	Moderate	Increased risk of ventricular arrhythmias by the combination of Trazodone and Galantamine.	Alzheimer disease [8A20]	[26]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Trazodone and Rivastigmine.	Alzheimer disease [8A20]	[26]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Trazodone and Metronidazole.	Amoebiasis [1A36]	[27]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Trazodone and Ivabradine.	Angina pectoris [BA40]	[25]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Trazodone and Dronedarone.	Angina pectoris [BA40]	[26]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Trazodone and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[28]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Cilostazol.	Arterial occlusive disease [BD40]	[24]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Trazodone and Levalbuterol.	Asthma [CA23]	[29]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Trazodone and Terbutaline.	Asthma [CA23]	[30]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Trazodone and Pirbuterol.	Asthma [CA23]	[30]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Trazodone and Salbutamol.	Asthma [CA23]	[29]
Formoterol	DMSOURV	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Formoterol.	Asthma [CA23]	[30]
Desipramine	DMT2FDC	Major	Additive serotonergic effects by the combination of Trazodone and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[19]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Trazodone caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[31]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Trazodone and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[26]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Trazodone and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[32]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[24]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[24]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[24]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Trazodone caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[31]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[24]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Trazodone caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[31]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Retigabine.	Behcet disease [4A62]	[24]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Loperamide.	Bowel habit change [ME05]	[33]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Eribulin.	Breast cancer [2C60-2C6Y]	[24]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Lapatinib.	Breast cancer [2C60-2C6Y]	[24]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Trazodone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[34]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Tamoxifen.	Breast cancer [2C60-2C6Y]	[24]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Bosutinib.	Breast cancer [2C60-2C6Y]	[25]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[24]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Trazodone and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[29]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Trazodone and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[30]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Trazodone and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[30]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Trazodone and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[30]
Dihydrocodeine	DMB0FWL	Moderate	Additive serotonergic effects by the combination of Trazodone and Dihydrocodeine.	Chronic pain [MG30]	[35]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Trazodone and Levomilnacipran.	Chronic pain [MG30]	[19]
Isoproterenol	DMK7MEY	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Isoproterenol.	Conduction disorder [BC63]	[29]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Trazodone and Olopatadine.	Conjunctiva disorder [9A60]	[36]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Halothane.	Corneal disease [9A76-9A78]	[24]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Propofol.	Corneal disease [9A76-9A78]	[37]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Sevoflurane.	Corneal disease [9A76-9A78]	[24]
Alfentanil	DMVO0UB	Moderate	Additive serotonergic effects by the combination of Trazodone and Alfentanil.	Corneal disease [9A76-9A78]	[35]
Remifentanil	DMZTXCH	Moderate	Additive CNS depression effects by the combination of Trazodone and Remifentanil.	Corneal disease [9A76-9A78]	[35]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Probucol.	Coronary atherosclerosis [BA80]	[24]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Clofazimine.	Crohn disease [DD70]	[24]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Trazodone and Mifepristone.	Cushing syndrome [5A70]	[26]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Trazodone and Pasireotide.	Cushing syndrome [5A70]	[26]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Osilodrostat.	Cushing syndrome [5A70]	[24]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Trazodone and Ethanol.	Cystitis [GC00]	[36]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Trazodone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[38]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Trazodone and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[39]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[26]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Ingrezza.	Dystonic disorder [8A02]	[24]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Trazodone caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Trazodone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[41]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Trazodone caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[25]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Trazodone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[42]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Solifenacin.	Functional bladder disorder [GC50]	[24]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Trazodone caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[43]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Trazodone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[31]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Pentamidine.	Fungal infection [1F29-1F2F]	[24]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Trazodone caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[44]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Trazodone caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[25]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Trazodone caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[31]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[24]
Ergotamine	DMKR3C5	Major	Additive serotonergic effects by the combination of Trazodone and Ergotamine.	Headache [8A80-8A84]	[19]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Trazodone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[45]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Trazodone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[45]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Trazodone caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[25]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Trazodone caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[46]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Trazodone and Procarbazine.	Hodgkin lymphoma [2B30]	[20]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Trazodone caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Trazodone caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Trazodone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Trazodone and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[47]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Trazodone caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[48]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Trazodone caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Trazodone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Trazodone caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Trazodone caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[27]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Trazodone caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[31]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Trazodone caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[49]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Trazodone caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[50]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Trazodone and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[26]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Trazodone and Phenolphthalein.	Irritable bowel syndrome [DD91]	[26]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Trazodone caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[25]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Trazodone and Crizotinib.	Lung cancer [2C25]	[51]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Trazodone caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[52]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Trazodone and Ceritinib.	Lung cancer [2C25]	[26]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Trazodone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[53]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Trazodone caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[54]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Trazodone and Osimertinib.	Lung cancer [2C25]	[55]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Trazodone and Selpercatinib.	Lung cancer [2C25]	[25]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Trazodone and Lumefantrine.	Malaria [1F40-1F45]	[27]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Trazodone and Halofantrine.	Malaria [1F40-1F45]	[56]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Trazodone and Hydroxychloroquine.	Malaria [1F40-1F45]	[57]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Primaquine.	Malaria [1F40-1F45]	[24]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[25]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Trazodone caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[58]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Trazodone and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[59]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Trazodone and Vemurafenib.	Melanoma [2C30]	[26]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and LGX818.	Melanoma [2C30]	[24]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Trazodone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[25]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Trazodone and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[60]
Almogran	DM7I64Z	Major	Additive serotonergic effects by the combination of Trazodone and Almogran.	Migraine [8A80]	[19]
Frovatriptan	DM7RE8P	Major	Additive serotonergic effects by the combination of Trazodone and Frovatriptan.	Migraine [8A80]	[19]
Rizatriptan	DMDJMA3	Major	Additive serotonergic effects by the combination of Trazodone and Rizatriptan.	Migraine [8A80]	[19]
Naratriptan	DMO50U2	Major	Additive serotonergic effects by the combination of Trazodone and Naratriptan.	Migraine [8A80]	[19]
Sumatriptan	DMVYXR8	Major	Additive serotonergic effects by the combination of Trazodone and Sumatriptan.	Migraine [8A80]	[19]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Trazodone caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[61]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Trazodone and Flibanserin.	Mood disorder [6A60-6E23]	[62]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Trazodone and Panobinostat.	Multiple myeloma [2A83]	[63]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Trazodone and Thalidomide.	Multiple myeloma [2A83]	[64]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Trazodone and Siponimod.	Multiple sclerosis [8A40]	[27]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Trazodone and Fingolimod.	Multiple sclerosis [8A40]	[26]
Ozanimod	DMT6AM2	Major	Additive serotonergic effects by the combination of Trazodone and Ozanimod.	Multiple sclerosis [8A40]	[20]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Romidepsin.	Mycosis fungoides [2B01]	[24]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Trazodone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[25]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Trazodone and Nilotinib.	Myeloproliferative neoplasm [2A20]	[26]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Dasatinib.	Myeloproliferative neoplasm [2A20]	[24]
Modafinil	DMYILBE	Minor	Increased metabolism of Trazodone caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[65]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Promethazine.	Nausea/vomiting [MD90]	[24]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Trazodone caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[66]
Granisetron	DMIUW25	Major	Increased risk of prolong QT interval by the combination of Trazodone and Granisetron.	Nausea/vomiting [MD90]	[26]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Trazodone and Dolasetron.	Nausea/vomiting [MD90]	[26]
Ondansetron	DMOTQ1I	Major	Additive serotonergic effects by the combination of Trazodone and Ondansetron.	Nausea/vomiting [MD90]	[26]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Trazodone and Bupropion.	Nicotine use disorder [6C4A]	[26]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Entrectinib.	Non-small cell lung cancer [2C25]	[27]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Trazodone and Sibutramine.	Obesity [5B80-5B81]	[67]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Trazodone and Lorcaserin.	Obesity [5B80-5B81]	[68]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Trazodone and Dexfenfluramine.	Obesity [5B80-5B81]	[19]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Trazodone and Levomethadyl Acetate.	Opioid use disorder [6C43]	[25]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Lofexidine.	Opioid use disorder [6C43]	[24]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Trazodone and Apraclonidine.	Optic nerve disorder [9C40]	[69]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Rucaparib.	Ovarian cancer [2C73]	[24]
Oxymorphone	DM65AGJ	Moderate	Additive CNS depression effects by the combination of Trazodone and Oxymorphone.	Pain [MG30-MG3Z]	[35]
Levorphanol	DMGS80V	Moderate	Additive CNS depression effects by the combination of Trazodone and Levorphanol.	Pain [MG30-MG3Z]	[35]
Dezocine	DMJDB0Y	Moderate	Additive CNS depression effects by the combination of Trazodone and Dezocine.	Pain [MG30-MG3Z]	[35]
Nalbuphine	DMOSQGU	Moderate	Additive CNS depression effects by the combination of Trazodone and Nalbuphine.	Pain [MG30-MG3Z]	[35]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Buprenorphine.	Pain [MG30-MG3Z]	[24]
Hydrocodone	DMQ2JO5	Moderate	Additive serotonergic effects by the combination of Trazodone and Hydrocodone.	Pain [MG30-MG3Z]	[35]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Triclabendazole.	Parasitic worm infestation [1F90]	[24]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Trazodone and Safinamide.	Parkinsonism [8A00]	[20]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Trazodone and Rasagiline.	Parkinsonism [8A00]	[20]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Pimavanserin.	Parkinsonism [8A00]	[70]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Trazodone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[71]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Famotidine.	Peptic ulcer [DA61]	[27]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Trazodone and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[72]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Trazodone and Lefamulin.	Pneumonia [CA40]	[73]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Trazodone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[74]
Ritodrine	DM4V6RL	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Ritodrine.	Preterm labour/delivery [JB00]	[30]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Degarelix.	Prostate cancer [2C82]	[25]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Trazodone caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[75]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Nilutamide.	Prostate cancer [2C82]	[25]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Enzalutamide.	Prostate cancer [2C82]	[25]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Relugolix.	Prostate cancer [2C82]	[25]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Bicalutamide.	Prostate cancer [2C82]	[25]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Levomepromazine.	Psychotic disorder [6A20-6A25]	[24]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Trazodone and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[76]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Trazodone and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[77]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Quetiapine.	Schizophrenia [6A20]	[24]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Trazodone and Mesoridazine.	Schizophrenia [6A20]	[26]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Trazodone and Thioridazine.	Schizophrenia [6A20]	[26]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Trazodone and Iloperidone.	Schizophrenia [6A20]	[26]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Paliperidone.	Schizophrenia [6A20]	[24]
Perphenazine	DMA4MRX	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Perphenazine.	Schizophrenia [6A20]	[24]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Trifluoperazine.	Schizophrenia [6A20]	[24]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Trazodone and Amisulpride.	Schizophrenia [6A20]	[78]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Trazodone and Pimozide.	Schizophrenia [6A20]	[25]
Fentanyl	DM8WAHT	Major	Additive serotonergic effects by the combination of Trazodone and Fentanyl.	Sensation disturbance [MB40]	[19]
Sufentanil	DMU7YEL	Moderate	Additive CNS depression effects by the combination of Trazodone and Sufentanil.	Sensation disturbance [MB40]	[35]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Vardenafil.	Sexual dysfunction [HA00-HA01]	[24]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Trazodone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[25]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Trazodone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[27]
Armodafinil	DMGB035	Minor	Increased metabolism of Trazodone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[65]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Trazodone and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[26]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[25]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[24]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Pitolisant.	Somnolence [MG42]	[24]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[24]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Trazodone caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[79]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Lenvatinib.	Thyroid cancer [2D10]	[24]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Trazodone and Cabozantinib.	Thyroid cancer [2D10]	[25]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Trazodone and Papaverine.	Tonus and reflex abnormality [MB47]	[80]
Tizanidine	DMR2IQ4	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Tizanidine.	Tonus and reflex abnormality [MB47]	[24]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Trazodone and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[76]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[24]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Trazodone and Procainamide.	Ventricular tachyarrhythmia [BC71]	[26]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Propafenone.	Ventricular tachyarrhythmia [BC71]	[24]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Trazodone and Flecainide.	Ventricular tachyarrhythmia [BC71]	[24]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Trazodone and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[26]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Calcium hydrogenphosphate	E00294	24441	Diluent
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Xylitol	E00136	6912	Coating agent; Diluent; Emollient; Flavoring agent; Humectant
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Trazodone 0.25 mg tablet	0.25 mg	12 HR Extended Release Oral Tablet	Oral
Trazodone 1 mg tablet	1 mg	12 HR Extended Release Oral Tablet	Oral
Trazodone 2.5 mg tablet	2.5 mg	12 HR Extended Release Oral Tablet	Oral
Trazodone 5 mg tablet	5 mg	12 HR Extended Release Oral Tablet	Oral
Trazodone 0.125 mg tablet	0.125 mg	12 HR Extended Release Oral Tablet	Oral
Trazodone Hydrochloride 50mg tablet	50mg	Tablet	Oral
Trazodone 100 mg tablet	100 mg	Oral Tablet	Oral
Trazodone 50 mg tablet	50 mg	Oral Tablet	Oral
Trazodone Hydrochloride 300mg tablet	300mg	Tablet	Oral
Trazodone Hydrochloride 150mg tablet	150mg	Tablet	Oral
Trazodone 150 mg tablet	150 mg	Oral Tablet	Oral
Trazodone 300 mg tablet	300 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 213).
• [2] Edson KZ, Prasad B, Unadkat JD, Suhara Y, Okano T, Guengerich FP, Rettie AE: Cytochrome P450-dependent catabolism of vitamin K: omega-hydroxylation catalyzed by human CYP4F2 and CYP4F11. Biochemistry. 2013 Nov 19;52(46):8276-85. doi: 10.1021/bi401208m. Epub 2013 Nov 7.
• [3] BDDCS applied to over 900 drugs
• [4] Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 1994 Apr;4(4):331-55. doi: 10.2165/00002512-199404040-00006.
• [5] Monograph, Trazodone
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [8] Nilsen OG, Dale O: Single dose pharmacokinetics of trazodone in healthy subjects. Pharmacol Toxicol. 1992 Aug;71(2):150-3.
• [9] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [11] Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact. 2005 Jun 30;155(1-2):10-20.
• [12] Evaluating the role of drug metabolism and reactive intermediates in trazodone-induced cytotoxicity toward freshly-isolated rat hepatocytes. Drug Res (Stuttg). 2016 Nov;66(11):592-596.
• [13] Drug Interactions Flockhart Table
• [14] Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. doi: 10.1007/BF02244985.
• [15] Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
• [16] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [17] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [18] Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
• [19] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
• [20] Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
• [21] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
• [22] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
• [23] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [24] Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
• [25] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [26] Canadian Pharmacists Association.
• [27] Cerner Multum, Inc. "Australian Product Information.".
• [28] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [29] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [30] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [31] Dattilo PB, Nordin C "Prolonged QT associated with an overdose of trazodone." J Clin Psychiatry 68 (2007): 1309-10. [PMID: 17854263]
• [32] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [33] Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
• [34] Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
• [35] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
• [36] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [37] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [38] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [39] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
• [40] Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
• [41] Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
• [42] Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
• [43] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [44] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
• [45] Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
• [46] Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [47] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [48] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [49] Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
• [50] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [51] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [52] Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [53] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [54] Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [55] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [56] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [57] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [58] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [59] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [60] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [61] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [62] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [63] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [64] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [65] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [66] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [67] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
• [68] Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
• [69] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [70] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [71] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [72] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [73] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [74] Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
• [75] Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
• [76] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [77] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [78] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [79] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [80] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]